Esomeprazole
- Generic Name
- Esomeprazole
- Brand Names
- Nexium, Vimovo, Nexium Control
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 119141-88-7
- Unique Ingredient Identifier
- N3PA6559FT
- Background
Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison ...
- Indication
Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions incl...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
- Associated Therapies
- -
Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Yanqing Li
- Target Recruit Count
- 368
- Registration Number
- NCT05870683
- Locations
- 🇨🇳
Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China
Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Finni Kollins
- Target Recruit Count
- 51
- Registration Number
- NCT05861687
- Locations
- 🇮🇩
Universitas Sumatera Utara General Hospital, Medan, North Sumatera, Indonesia
🇮🇩Haji Adam Malik General Hospital, Medan, North Sumatera, Indonesia
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 32
- Registration Number
- NCT05826574
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 120
- Registration Number
- NCT05742568
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Shanghai East Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05726734
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 338
- Registration Number
- NCT05701540
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
A Study of IBI351 in Healthy Subjects
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05688124
- Locations
- 🇨🇳
the First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( TATH-1 )
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Zhang Xiaofeng,MD
- Target Recruit Count
- 100
- Registration Number
- NCT05647278
- Locations
- 🇨🇳
Hangzhou first people's Hospital, Hangzhou, Zhejiang, China
A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- First People's Hospital of Hangzhou
- Target Recruit Count
- 100
- Registration Number
- NCT05590286
- Locations
- 🇨🇳
Hangzhou first people's Hospital, Hangzhou, Zhejiang, China
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 594
- Registration Number
- NCT05582174
- Locations
- 🇨🇳
Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Shenzhen Pingshan District People's Hospital, Shenzhen, Guangdong, China
🇨🇳The Second Affiliated Hospital The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.